To date, the company has raised $42 million to develop its transcatheter mitral valve repair system.

Yousif Ahmad, MD, spoke with Cardiovascular Business about the latest advances in IVL therapy, including new reimbursement changes for the technology. 

Congress has already adjourned for the year without taking action, but U.S. medical societies are hoping relief from significant Medicare cuts will arrive in early 2024. 

The company and one of its subsidiaries would allegedly confuse clinicians and have them bill government programs for cardiac monitoring services that were more expensive than what they needed. This settlement resolves those allegations. 

The Lower Costs, More Transparency Act requires radiologists to publicly list prices for certain "shoppable" services.

The company's Verafeye platform was designed to provide imaging guidance during cardiac procedures using advanced catheter sensors and deep learning. 

The doctor allegedly targeted some patients more than ten times, treating them again and again with procedures that were not medically necessary. 

Prosecutors successfully argued that the patient would not have died if clinicians had ordered a routine CT exam.